158 related articles for article (PubMed ID: 32843487)
21. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
Apostolou P; Fostira F; Kouroussis C; Kalfakakou D; Delimitsou A; Agelaki S; Androulakis N; Christodoulou C; Kalbakis K; Kalykaki A; Sanidas E; Papadimitriou C; Vamvakas L; Georgoulias V; Mavroudis D; Yannoukakos D; Konstantopoulou I; Saloustros E
Int J Cancer; 2020 Sep; 147(5):1334-1342. PubMed ID: 32022259
[TBL] [Abstract][Full Text] [Related]
23. Male with an apparently normal phenotype carrying a BRCA1 exon 20 duplication in trans to a BRCA1 frameshift variant.
Block I; Mateu-Regué À; Do TTN; Miceikaite I; Sdogati D; Larsen MJ; Hao Q; Nielsen HR; Boonen SE; Skytte AB; Jensen UB; Høffding LK; De Nicolo A; Viel A; Tudini E; Parsons MT; Hansen TVO; Rossing M; Kruse TA; Spurdle AB; Thomassen M
Breast Cancer Res; 2024 Jan; 26(1):6. PubMed ID: 38195559
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients.
Gao X; Nan X; Liu Y; Liu R; Zang W; Shan G; Gai F; Zhang J; Li L; Cheng G; Song L
Hum Mutat; 2020 Mar; 41(3):696-708. PubMed ID: 31825140
[TBL] [Abstract][Full Text] [Related]
25. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
26. Can the Synergic Contribution of Multigenic Variants Explain the Clinical and Cellular Phenotypes of a Neurodevelopmental Disorder?
Maia N; Nabais Sá MJ; Oliveira C; Santos F; Soares CA; Prior C; Tkachenko N; Santos R; de Brouwer APM; Jacome A; Porto B; Jorge P
Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052418
[TBL] [Abstract][Full Text] [Related]
27. Retesting of women who are negative for a
Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS
J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482
[TBL] [Abstract][Full Text] [Related]
28. Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia.
Bogliolo M; Bluteau D; Lespinasse J; Pujol R; Vasquez N; d'Enghien CD; Stoppa-Lyonnet D; Leblanc T; Soulier J; Surrallés J
Genet Med; 2018 Apr; 20(4):458-463. PubMed ID: 28837157
[TBL] [Abstract][Full Text] [Related]
29. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
[TBL] [Abstract][Full Text] [Related]
30.
Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
[TBL] [Abstract][Full Text] [Related]
31. Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families.
de Garibay GR; Díaz A; Gaviña B; Romero A; Garre P; Vega A; Blanco A; Tosar A; Díez O; Pérez-Segura P; Díaz-Rubio E; Caldés T; de la Hoya M
Eur J Hum Genet; 2013 Aug; 21(8):883-6. PubMed ID: 23211700
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
[TBL] [Abstract][Full Text] [Related]
33. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype.
Snell C; Krypuy M; Wong EM; ; Loughrey MB; Dobrovic A
Breast Cancer Res; 2008; 10(1):R12. PubMed ID: 18269736
[TBL] [Abstract][Full Text] [Related]
34. A novel splice site mutation in the noncoding region of BRCA2: implications for Fanconi anemia and familial breast cancer diagnostics.
Bakker JL; Thirthagiri E; van Mil SE; Adank MA; Ikeda H; Verheul HM; Meijers-Heijboer H; de Winter JP; Sharan SK; Waisfisz Q
Hum Mutat; 2014 Apr; 35(4):442-6. PubMed ID: 24395671
[TBL] [Abstract][Full Text] [Related]
35. Nijmegen breakage syndrome (NBS).
Chrzanowska KH; Gregorek H; Dembowska-Bagińska B; Kalina MA; Digweed M
Orphanet J Rare Dis; 2012 Feb; 7():13. PubMed ID: 22373003
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
[TBL] [Abstract][Full Text] [Related]
37. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.
Domchek SM; Tang J; Stopfer J; Lilli DR; Hamel N; Tischkowitz M; Monteiro AN; Messick TE; Powers J; Yonker A; Couch FJ; Goldgar DE; Davidson HR; Nathanson KL; Foulkes WD; Greenberg RA
Cancer Discov; 2013 Apr; 3(4):399-405. PubMed ID: 23269703
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
Spurdle AB; Whiley PJ; Thompson B; Feng B; Healey S; Brown MA; Pettigrew C; ; Van Asperen CJ; Ausems MG; Kattentidt-Mouravieva AA; van den Ouweland AM; ; Lindblom A; Pigg MH; Schmutzler RK; Engel C; Meindl A; ; Caputo S; Sinilnikova OM; Lidereau R; ; Couch FJ; Guidugli L; Hansen Tv; Thomassen M; Eccles DM; Tucker K; Benitez J; Domchek SM; Toland AE; Van Rensburg EJ; Wappenschmidt B; Borg Å; Vreeswijk MP; Goldgar DE;
J Med Genet; 2012 Aug; 49(8):525-32. PubMed ID: 22889855
[TBL] [Abstract][Full Text] [Related]
39. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
[TBL] [Abstract][Full Text] [Related]
40. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
